PE20070532A1 - COMPUESTOS DERIVADOS DE TIENO[3,2-d]PIRIMIDIN COMO ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA - Google Patents

COMPUESTOS DERIVADOS DE TIENO[3,2-d]PIRIMIDIN COMO ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA

Info

Publication number
PE20070532A1
PE20070532A1 PE2006001304A PE2006001304A PE20070532A1 PE 20070532 A1 PE20070532 A1 PE 20070532A1 PE 2006001304 A PE2006001304 A PE 2006001304A PE 2006001304 A PE2006001304 A PE 2006001304A PE 20070532 A1 PE20070532 A1 PE 20070532A1
Authority
PE
Peru
Prior art keywords
pyrimidin
antagonists
alkyl
hormone receptor
chlorophenyl
Prior art date
Application number
PE2006001304A
Other languages
English (en)
Inventor
Andres S Hernandez
William N Washburn
Mark C Manfredi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20070532A1 publication Critical patent/PE20070532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R1 ES H, HALOGENO, ALQUILO(C1-C8), CICLOALQUILO(C3-C10), ENTRE OTROS; R2 ES H O ALQUILO(C1-C8); R4 ES HIDROXILO O G-D2-Zn, DONDE n ES DE 1 A 3; G ES UN ENLACE DIRECTO, O, S, ENTRE OTROS; D2 ES UN ENLACE DIRECTO, ALQUILO(C1-C8), CICLOALQUILO(C3-C10), ENTRE OTROS; Z ES H, ALCOXI(C1-C8), HALOGENO, ENTRE OTROS; R5 ES H, HALOGENO, ALQUILO(C1-C8), ENTRE OTROS; m ES 0 O 1. SON COMPUESTOS PREFERIDOS: N-(2-(4-(6-(4-CLOROFENIL)-4-OXOTIENO[3,2-d]PIRIMIDIN-3(4H)-IL)-2-METOXIFENOXI)ETIL)PIVALAMIDA, N-(2-(4-(6-(4-CLOROFENIL)-4-OXOTIENO[3,2-d]PIRIMIDIN-3(4H)-IL)-2-METOXIFENOXI)ETIL)-N-ETILACETAMIDA, 2-(4-(6-(4-CLOROFENIL)-4-OXOTIENO[3,2-d]PIRIMIDIN-3(4H)-IL)-2-METOXIFENOXI)ETILCARBAMATO DE TER-BUTILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA (MCHR1) SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, DIABETES TIPO II, DEPRESION, ANSIEDAD
PE2006001304A 2005-10-26 2006-10-26 COMPUESTOS DERIVADOS DE TIENO[3,2-d]PIRIMIDIN COMO ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA PE20070532A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73045305P 2005-10-26 2005-10-26
US11/586,255 US8618115B2 (en) 2005-10-26 2006-10-25 Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them

Publications (1)

Publication Number Publication Date
PE20070532A1 true PE20070532A1 (es) 2007-06-14

Family

ID=37888159

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001304A PE20070532A1 (es) 2005-10-26 2006-10-26 COMPUESTOS DERIVADOS DE TIENO[3,2-d]PIRIMIDIN COMO ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA

Country Status (16)

Country Link
US (1) US8618115B2 (es)
EP (2) EP1948665B1 (es)
JP (1) JP2009513658A (es)
KR (1) KR20080067681A (es)
AR (1) AR056155A1 (es)
AU (1) AU2006306140A1 (es)
BR (1) BRPI0617945A2 (es)
CA (1) CA2627653A1 (es)
EA (1) EA016126B1 (es)
GE (1) GEP20115213B (es)
IL (1) IL190898A0 (es)
NO (1) NO20081772L (es)
NZ (1) NZ567659A (es)
PE (1) PE20070532A1 (es)
TW (1) TW200728289A (es)
WO (1) WO2007050726A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285557B2 (en) * 2001-10-15 2007-10-23 Smithkline Beecham P.L.C. Pyrimidinones as melanin concentrating hormone receptor 1
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2008061109A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CN102272135A (zh) * 2008-10-08 2011-12-07 百时美施贵宝公司 唑并吡咯酮黑色素浓集激素受体-1拮抗剂
WO2010042682A1 (en) 2008-10-08 2010-04-15 Bristol-Myers Squibb Company Azolotriazinone melanin concentrating hormone receptor-1 antagonists
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2405913A1 (en) 2009-03-09 2012-01-18 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2010104818A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
CN103130819B (zh) * 2011-12-01 2016-01-20 中国科学院上海药物研究所 噻吩[3,2-d]并嘧啶-4-酮类化合物、其制备方法、药物组合物及用途
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253759A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
HUE051395T2 (hu) 2015-12-09 2021-03-01 Cadent Therapeutics Inc Heteroaromás NMDA receptor modulátorok és alkalmazásaik
CN107216339B (zh) * 2016-03-22 2021-05-04 中国科学院上海药物研究所 一种dppiv抑制剂马来酸盐的多晶型及其制备方法
ES2975336T3 (es) 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
PE20210948A1 (es) 2018-08-03 2021-05-24 Cadent Therapeutics Inc Moduladores del receptor nmda heteroaromatico y usos de los mismos

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) * 1974-06-07 1981-03-18
JPS5432794A (en) 1977-08-18 1979-03-10 Omron Tateisi Electronics Co Manufacturing method of terminal rack
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
JPS62501009A (ja) 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
WO1987002662A2 (en) 1985-10-25 1987-05-07 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3817375C2 (de) 1987-05-22 1997-04-30 Squibb & Sons Inc Phosphorhaltige HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9209628D0 (en) * 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5470845A (en) * 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5662934A (en) 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
AU1108395A (en) 1993-12-07 1995-06-27 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
WO1997048701A1 (en) 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6482821B2 (en) * 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1255043A (zh) 1997-05-08 2000-05-31 英国阿格里沃有限公司 杀真菌剂
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
NZ503794A (en) 1997-10-08 2002-09-27 Sankyo Co Benzimidazole and imidazopyridine derived heterocyclic compounds, pharmaceutical compositions and uses thereof
RU2001103044A (ru) 1998-07-06 2003-08-10 Бристол-Маерс Сквибб Ко. (Us) Бенилсульфонамиды в качестве двойных антагонистов ангиотензиновых эндотелиновых рецепторов
AU5612199A (en) 1998-09-10 2000-04-03 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
AU767245B2 (en) 1998-11-25 2003-11-06 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
EP1155121B1 (en) 1999-02-24 2006-04-26 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
WO2000073288A1 (en) 1999-05-28 2000-12-07 Vertex Pharmaceuticals Incorporated Method for preparing 5-substituted oxazoles
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2002010146A1 (en) 2000-07-31 2002-02-07 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
WO2002101146A1 (fr) 2001-05-11 2002-12-19 Arina Nakayama Papier lumineux et son procede de production et d'utilisation
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
CZ2004634A3 (cs) 2001-10-25 2004-10-13 Takedaáchemicaláindustriesźáltd Chinolinová sloučeninaŹ způsob výroby a použití a farmaceutický přípravek
EP1572682A4 (en) 2002-12-20 2008-01-23 Pharmacia Corp ACYCLIC PYRAZOLE COMPOUNDS
WO2004092181A1 (en) 2003-04-11 2004-10-28 Smithkline Beecham Corporation Heterocyclic mchr1 antagonists
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005042541A1 (en) 2003-10-23 2005-05-12 Glaxo Group Limited 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20050256124A1 (en) 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists

Also Published As

Publication number Publication date
NZ567659A (en) 2011-06-30
EP1948665A2 (en) 2008-07-30
EA200801165A1 (ru) 2008-10-30
JP2009513658A (ja) 2009-04-02
US20070093509A1 (en) 2007-04-26
AU2006306140A1 (en) 2007-05-03
CA2627653A1 (en) 2007-05-03
US8618115B2 (en) 2013-12-31
BRPI0617945A2 (pt) 2011-08-09
EP2298776A1 (en) 2011-03-23
WO2007050726A3 (en) 2007-08-30
EA016126B1 (ru) 2012-02-28
NO20081772L (no) 2008-05-19
KR20080067681A (ko) 2008-07-21
EP1948665B1 (en) 2013-02-27
GEP20115213B (en) 2011-05-10
AR056155A1 (es) 2007-09-19
WO2007050726A2 (en) 2007-05-03
IL190898A0 (en) 2008-11-03
TW200728289A (en) 2007-08-01

Similar Documents

Publication Publication Date Title
PE20070532A1 (es) COMPUESTOS DERIVADOS DE TIENO[3,2-d]PIRIMIDIN COMO ANTAGONISTAS DEL RECEPTOR 1 DE LA HORMONA DE CONCENTRACION DE MELANINA
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20130242A1 (es) Derivados de isoxazolo-piridina
PE20090718A1 (es) Derivados de espiroindolinona
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
CO6351730A2 (es) Derivados de pirazolo(3,4)pirimidim - 4-il y sus usos para tratar diabetes y obesidad
UY29145A1 (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20060487A1 (es) Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas
BRPI0514661A (pt) antagonistas de vasopressina v1a
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
ES2337596T3 (es) Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
CR9389A (es) Compuestos de imidazopiridazina
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
PE20081228A1 (es) Compuesto heteromonociclico
PE20081346A1 (es) Derivados de espiroindolinona como antagonistas de mdm2
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm

Legal Events

Date Code Title Description
FC Refusal